ARPC5L

Across TCGA pan-cancer cohorts, ARPC5L RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of ARPC5L’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where ARPC5L RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARPC5L is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

COAD, LIHC, and LUAD are the cancer types where ARPC5L tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARPC5L RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	II,III,IV	+0.815	<.001	12	view →
LIHC	Female	II,III,IV	+0.853	<.001	9	view →
LUAD	All	III,IV	+0.497	<.001	9	view →
LUSC	Female	All	+0.817	<.001	8	view →
HNSC	Male	All	+0.816	<.001	8	view →
STAD	All	II,III,IV	+0.769	<.001	8	view →
THCA	Male	All	+0.582	<.001	8	view →
UCEC	All	III,IV	+1.093	<.001	6	view →
BRCA	All	III,IV	+0.758	<.001	6	view →
BLCA	All	III,IV	+0.683	.009	6	view →
CHOL	Male	All	+1.926	<.001	4	view →
READ	All	All	+0.556	.010	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

ARPC5L–COAD

Open the COAD breakdown →